CompletedPHASE1, PHASE2NCT00004084
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia
Studying Epstein-Barr virus-associated malignant lymphoproliferative disorder
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Garden State Cancer Center at the Center for Molecular Medicine and Immunology
- Principal Investigator
- Jack D. Burton, MDGarden State Cancer Center at the Center for Molecular Medicine and Immunology
- Intervention
- indium In 111 LL2 IgG(radiation)
- Enrollment
- 21 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 1998
Study locations (2)
- Garden State Cancer Center, Belleville, New Jersey, United States
- University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00004084 on ClinicalTrials.govOther trials for Epstein-Barr virus-associated malignant lymphoproliferative disorder
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07381738Unrelated Cord Blood Transplantation for EBV-associated Lymphoproliferative DisordersFudan University
- RECRUITINGPHASE1, PHASE2NCT07450391EBV-AST Cell Injection for EBV-Associated Lymphoproliferative DisordersDaihong Liu
See all trials for Epstein-Barr virus-associated malignant lymphoproliferative disorder →